Last reviewed · How we verify
NCT06588296
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Completed
Phase 3
What this trial tests
Phase 3 trial testing Ixekizumab in Psoriatic Arthritis in 279 participants. Completed in 23 April 2026.
Timeline
24 September 2024
23 April 2026
Quick facts
| Lead sponsor | Eli Lilly and Company |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Enrollment | 279 |
| Start date | 24 September 2024 |
| Estimated completion | 23 April 2026 |
Drugs / interventions tested
- Ixekizumab (ixekizumab) — full drug profile →
- Tirzepatide (TIRZEPATIDE) — full drug profile →
Conditions studied
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
- Obesity — all drugs for Obesity →
Sponsor
Eli Lilly and Company — full company profile →
Who can join
Eligibility, any sex, with Psoriatic Arthritis or Obesity.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.
Buonanno S, Gaggiano C, Terribili R, Cantarini L, et al · · 2025 · cited 4× · PMID 41266905 · DOI 10.1007/s00011-025-02140-2 -
Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.
Ciancio G, Maranini B, Sandri G, Amati G, et al · · 2026 · PMID 42131335 · DOI 10.3389/fimmu.2026.1744308 -
Editorial: Exploring innovative therapies for rare inflammatory skin diseases.
Niebel D, Miše J, Wenzel J. · · 2026 · PMID 41939760 · DOI 10.3389/fmed.2026.1822888 -
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Merola JF, Mease P, Kivitz A, Sattar N, et al · · 2026 · PMID 41903163 · DOI 10.1002/art.70134 -
The role of the incretin GIP in inflammation.
Rossi G, Bucciarelli L, Cimino V, Fiorina P. · · 2026 · PMID 41082103 · DOI 10.1007/s40618-025-02719-w
Verify or expand the search:
- PubMed search for NCT06588296
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ixekizumab
Trials testing the same drug.
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT07200986 — Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects · Phase 1 · active not recruiting
- NCT06786936 — Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms · recruiting
- NCT06945107 — A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin · Phase 3 · active not recruiting
- NCT06811558 — Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis · NA · not yet recruiting
Other recruiting trials for Psoriatic Arthritis
Currently open trials in the same condition.
- NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
- NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
Other Eli Lilly and Company trials
Trials by the same sponsor.
- NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
- NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
- NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
- NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
- NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06588296 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
- Last refreshed: recently
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06588296.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing